Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 6
1990 3
1991 6
1992 6
1993 2
1994 1
1995 3
1997 2
1998 2
1999 1
2001 2
2004 3
2005 2
2006 3
2007 1
2008 3
2010 3
2011 1
2013 3
2015 1
2016 5
2017 3
2018 7
2019 11
2020 8
2021 15
2022 16
2023 10
2024 18
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for tcr rg
Search for Tur RG instead (1 results)
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R, Bobisse S, Chiffelle J, Arnaud M, Petremand R, Queiroz L, Michel A, Reichenbach P, Cesbron J, Auger A, Baumgaertner P, Guillaume P, Schmidt J, Irving M, Kandalaft LE, Speiser DE, Coukos G, Harari A. Genolet R, et al. Cell Rep Methods. 2023 Apr 24;3(4):100459. doi: 10.1016/j.crmeth.2023.100459. eCollection 2023 Apr 24. Cell Rep Methods. 2023. PMID: 37159666 Free PMC article.
We also present a TCR cloning strategy to specifically amplify TCRs from T cell populations. Positioned downstream of single-cell or bulk TCR sequencing, it allows time- and cost-effective discovery, cloning, screening, and engineering of tumor-specific TCRs. Togeth …
We also present a TCR cloning strategy to specifically amplify TCRs from T cell populations. Positioned downstream of single-cell or …
Multiple early factors anticipate post-acute COVID-19 sequelae.
Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, Hong S, Zhang R, Xie J, Kornilov SA, Scherler K, Pavlovitch-Bedzyk AJ, Dong S, Lausted C, Lee I, Fallen S, Dai CL, Baloni P, Smith B, Duvvuri VR, Anderson KG, Li J, Yang F, Duncombe CJ, McCulloch DJ, Rostomily C, Troisch P, Zhou J, Mackay S, DeGottardi Q, May DH, Taniguchi R, Gittelman RM, Klinger M, Snyder TM, Roper R, Wojciechowska G, Murray K, Edmark R, Evans S, Jones L, Zhou Y, Rowen L, Liu R, Chour W, Algren HA, Berrington WR, Wallick JA, Cochran RA, Micikas ME; ISB-Swedish COVID-19 Biobanking Unit; Wrin T, Petropoulos CJ, Cole HR, Fischer TD, Wei W, Hoon DSB, Price ND, Subramanian N, Hill JA, Hadlock J, Magis AT, Ribas A, Lanier LL, Boyd SD, Bluestone JA, Chu H, Hood L, Gottardo R, Greenberg PD, Davis MM, Goldman JD, Heath JR. Su Y, et al. Cell. 2022 Mar 3;185(5):881-895.e20. doi: 10.1016/j.cell.2022.01.014. Epub 2022 Jan 25. Cell. 2022. PMID: 35216672 Free PMC article.
Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.
Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, Voillet V, Duvvuri VR, Scherler K, Troisch P, Baloni P, Qin G, Smith B, Kornilov SA, Rostomily C, Xu A, Li J, Dong S, Rothchild A, Zhou J, Murray K, Edmark R, Hong S, Heath JE, Earls J, Zhang R, Xie J, Li S, Roper R, Jones L, Zhou Y, Rowen L, Liu R, Mackay S, O'Mahony DS, Dale CR, Wallick JA, Algren HA, Zager MA; ISB-Swedish COVID19 Biobanking Unit; Wei W, Price ND, Huang S, Subramanian N, Wang K, Magis AT, Hadlock JJ, Hood L, Aderem A, Bluestone JA, Lanier LL, Greenberg PD, Gottardo R, Davis MM, Goldman JD, Heath JR. Su Y, et al. Cell. 2020 Dec 10;183(6):1479-1495.e20. doi: 10.1016/j.cell.2020.10.037. Epub 2020 Oct 28. Cell. 2020. PMID: 33171100 Free PMC article. Clinical Trial.
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.
Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, Templeton ML, Muhunthan V, Voillet V, Sommermeyer D, Whiteaker JR, Gottardo R, Veatch SL, Paulovich AG, Riddell SR. Salter AI, et al. Sci Signal. 2021 Aug 24;14(697):eabe2606. doi: 10.1126/scisignal.abe2606. Sci Signal. 2021. PMID: 34429382 Free PMC article.
Although CARs were designed to mimic T cell receptor (TCR) signaling, TCRs are at least 100-fold more sensitive to antigen. To design a CAR with improved antigen sensitivity, we directly compared TCR and CAR signaling in primary human T cells. Global phosphoproteomi …
Although CARs were designed to mimic T cell receptor (TCR) signaling, TCRs are at least 100-fold more sensitive to antigen. To design …
Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.
Rashid MH. Rashid MH. MAbs. 2022 Jan-Dec;14(1):2111748. doi: 10.1080/19420862.2022.2111748. MAbs. 2022. PMID: 36018829 Free PMC article. Review.
This review summarizes recent research, preclinical advancements, and clinical development of E. coli-produced aglycosylated therapeutic antibodies as monoclonal, bispecific, and antibody-drug conjugates for use in autoimmune, oncology, and immuno-oncology areas.Abbreviations: AD …
This review summarizes recent research, preclinical advancements, and clinical development of E. coli-produced aglycosylated therapeutic ant …
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, Woodward KB, Vartanian N, Kanaan SB, Yeh AC, Dossa RG, Bar M, Cassaday RD, Dahlberg A, Till BG, Denker AE, Yeung CCS, Gooley TA, Maloney DG, Riddell SR, Greenberg PD, Chapuis AG, Newell EW, Furlan SN, Bleakley M. Krakow EF, et al. Blood. 2024 Sep 5;144(10):1069-1082. doi: 10.1182/blood.2024024105. Blood. 2024. PMID: 38683966 Free PMC article. Clinical Trial.
T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific for hematopoietic-restricted minor histocompatibility (H) antigens may provide a potent selective antileukemic effect post-HCT. ...The primary objective was to evaluate the feasibi …
T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific for hematopoietic-restricted minor histo …
Early methionine availability attenuates T cell exhaustion.
Sharma P, Guo A, Poudel S, Boada-Romero E, Verbist KC, Palacios G, Immadisetty K, Chen MJ, Haydar D, Mishra A, Peng J, Babu MM, Krenciute G, Glazer ES, Green DR. Sharma P, et al. Nat Immunol. 2025 Aug;26(8):1384-1396. doi: 10.1038/s41590-025-02223-6. Epub 2025 Jul 23. Nat Immunol. 2025. PMID: 40702340 Free PMC article.
T cell receptor (TCR) activation is regulated in many ways, including niche-specific nutrient availability. Here we investigated how methionine (Met) availability and TCR signaling interplay during the earliest events of T cell activation affect subsequent cell fate …
T cell receptor (TCR) activation is regulated in many ways, including niche-specific nutrient availability. Here we investigated how …
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Abbas HA, et al. Nat Commun. 2021 Oct 18;12(1):6071. doi: 10.1038/s41467-021-26282-z. Nat Commun. 2021. PMID: 34663807 Free PMC article.
In contrast to the curative effect of allogenic stem cell transplantation in acute myeloid leukemia via T cell activity, only modest responses are achieved with checkpoint-blockade therapy, which might be explained by T cell phenotypes and T cell receptor (TCR) repertoires …
In contrast to the curative effect of allogenic stem cell transplantation in acute myeloid leukemia via T cell activity, only modest respons …
Engineered CD47 protects T cells for enhanced antitumour immunity.
Yamada-Hunter SA, Theruvath J, McIntosh BJ, Freitas KA, Lin F, Radosevich MT, Leruste A, Dhingra S, Martinez-Velez N, Xu P, Huang J, Delaidelli A, Desai MH, Good Z, Polak R, May A, Labanieh L, Bjelajac J, Murty T, Ehlinger Z, Mount CW, Chen Y, Heitzeneder S, Marjon KD, Banuelos A, Khan O, Wasserman SL, Spiegel JY, Fernandez-Pol S, Kuo CJ, Sorensen PH, Monje M, Majzner RG, Weissman IL, Sahaf B, Sotillo E, Cochran JR, Mackall CL. Yamada-Hunter SA, et al. Nature. 2024 Jun;630(8016):457-465. doi: 10.1038/s41586-024-07443-8. Epub 2024 May 15. Nature. 2024. PMID: 38750365 Free PMC article.
To overcome this challenge, we engineered the CD47 variant CD47(Q31P) (47(E)), which engages SIRPalpha and provides a 'don't eat me' signal that is not blocked by anti-CD47 antibodies. TCR or CAR T cells expressing 47(E) are resistant to clearance by macrophages after trea …
To overcome this challenge, we engineered the CD47 variant CD47(Q31P) (47(E)), which engages SIRPalpha and provides a 'don't eat me' signal …
A general system for targeting MHC class II-antigen complex via a single adaptable loop.
Du H, Liu J, Jude KM, Yang X, Li Y, Bell B, Yang H, Kassardjian A, Blackson W, Mobedi A, Parekh U, Parra Sperberg RA, Julien JP, Mellins ED, Garcia KC, Huang PS. Du H, et al. Nat Biotechnol. 2025 Oct;43(10):1673-1682. doi: 10.1038/s41587-024-02466-y. Epub 2024 Dec 13. Nat Biotechnol. 2025. PMID: 39672953 Free PMC article.
Targeting peptide-MHCII with T cell antigen receptors (TCRs) and TCR-like antibodies has shown promise for autoimmune diseases and microbiome tolerance. ...
Targeting peptide-MHCII with T cell antigen receptors (TCRs) and TCR-like antibodies has shown promise for autoimmune diseases and mi …
156 results